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Abstract: Varicella-zoster virus (VZV), an exclusively human herpesvirus, causes chickenpox and
establishes a latent infection in ganglia, reactivating decades later to produce zoster and associated
neurological complications. An understanding of VZV neurotropism in humans has long been
hampered by the lack of an adequate animal model. For example, experimental inoculation of VZV
in small animals including guinea pigs and cotton rats results in the infection of ganglia but not
a rash. The severe combined immune deficient human (SCID-hu) model allows the study of VZV
neurotropism for human neural sub-populations. Simian varicella virus (SVV) infection of rhesus
macaques (RM) closely resembles both human primary VZV infection and reactivation, with analyses
at early times after infection providing valuable information about the extent of viral replication
and the host immune responses. Indeed, a critical role for CD4 T-cell immunity during acute SVV
infection as well as reactivation has emerged based on studies using RM. Herein we discuss the
results of efforts from different groups to establish an animal model of VZV neurotropism.
Keywords: varicella zoster virus; animal models; simian varicella virus
1. Introduction
Varicella-zoster virus (VZV), a member of the human alphaherpesvirus family, causes chickenpox
(varicella) mostly in children and establishes a latent infection in cranial, dorsal root and autonomic
ganglia. Latent VZV can reactivate decades later to produce shingles (zoster). VZV-specific
cell-mediated immunity (CMI) declines with age, resulting in zoster and associated neurological
complications that are also seen in immunocompromised organ transplant recipients and in patients
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with cancer or AIDS. The actual mechanism of reduction in VZV-specific CMI and associated virus
reactivation remains unclear. VZV produces chickenpox and shingles only in humans, underscoring
the need for an animal model to study VZV neuropathogenesis. Attempts by multiple groups
to establish VZV infection in guinea pigs and mice by experimental inoculation have resulted in
seroconversion without clinical symptoms [1–6]. On the other hand, simian varicella virus (SVV)
infection in non-human primates (NHP) results in varicella. Although the NHP model is expensive,
it has provided critical insights into varicella pathogenesis and neurotropism not available with any of
the other models. Herein, we review the existing animal models of VZV neurotropism.
2. Infection of Guinea Pigs with Varicella-Zoster Virus
2.1. Initial Approaches
There is a strong belief, reflected in the introductions to many papers, that VZV grows only
in human cells. Although humans are its only natural host and VZV was first cultured in cells of
human origin [7], early studies revealed that VZV could also be propagated in cells from guinea pig
embryos [8,9]; nevertheless, because VZV multiplies to a greater extent in human than in guinea pig
cell cultures, human cells are almost always selected for research on VZV. Takahashi and colleagues,
however, took advantage of the ability of VZV to infect guinea pig cells and passaged VZV several
times in guinea pig fibroblasts as part of their effort to attenuate the virus for use as a live varicella
vaccine. The first study describing the development and use of the live attenuated varicella vaccine
appeared in 1974 [10] and the critical prospective study that showed its efficacy in children with
leukemia who were at risk of death from varicella appeared in 1984 [11]. This vaccine, now given in
two doses [12], has stably retained its efficacy [13] and has been modified to protect at-risk elderly
individuals from zoster [14].
2.2. First Guinea Pig Models of VZV
It took another decade for investigators to explore the use of guinea pigs as in vivo models of VZV
infection. This exploration included ocular infections, such as keratitis, and latency in the trigeminal
ganglion [15,16]. In analyses to investigate the ability of immunization to protect the eye from VZV
infection, guinea pigs were immunized with VZV glycoproteins E and I (gE and gI), followed by
inoculation of VZV into the vitreous of the eye, leading to chronic uveitis as well as involvement of the
lungs and central nervous system (CNS) in the non-immunized animals. Later investigators failed
to duplicate such extensive VZV infection of guinea pigs, although different routes of infection were
utilized [17]; nevertheless, prior immunization of guinea pigs appeared to partially protect them from
vitreal infection with VZV [18].
Several investigators used what were then newly developed molecular diagnostic techniques
(e.g., polymerase chain reaction, PCR) to test the usefulness of guinea pigs as models for the study of
VZV pathogenesis, clinical disease and antiviral therapy [2–4,19]. Using weanling animals, which were
presumably more susceptible to infection, and hairless guinea pigs to enable ready detection of a rash,
the investigators found that infections of the animals were more apparent if the VZV inoculum had first
been adapted to growth in guinea pig cells. In all cases, the inoculum consisted of cells in which the
virus was cultured; in no case was cell-free VZV or VZV-infected lymphocytes, which carry VZV during
viremia, used to infect animals. The investigators were able to document cell-associated viremia and
nasopharyngeal infection in weanling guinea pigs, although the animals did not become ill. Infection
was successful when the inoculum was administered intranasally, subcutaneously and intracranially,
whereas transmission of VZV to uninfected weanling animals in the same cage was limited when
VZV was administered intranasally. Transmission of infection, however, was documented, not by
observation of a transmitted illness, but by the seroconversion of rare exposed animals. A mild papular
rash was noted in 5–70% of VZV-inoculated animals, but no vesicles characteristic of human varicella
were observed. Hypothermia occurred in some animals and weight gain was depressed, but the
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animals were not otherwise ill. Overall, the guinea pigs were described as minimally symptomatic
from VZV infection. Infections were most prominent in hairless animals, less in strain 2 guinea pigs
and even less in outbred animals [2–4,9]. Pretreatment with cyclophosphamide, methotrexate and
steroids to induce immunosuppression did not appear to enhance the severity of infection [17]. No
VZV was isolated from the infected guinea pigs, although PCR amplification detected viral DNA
in the skin and blood of animals inoculated with VZV. Latent infection with VZV was suspected in
some of the VZV-infected guinea pigs, but this suspicion could not be verified because reactivation
of VZV from latency could not be demonstrated. The main obstacle to success with the guinea pig
studies in providing a clinical model for the study of VZV was thought to rest in a low multiplicity of
VZV infection in these animals [17]. Subsequent guinea pig studies by Arvin and colleagues [20–24]
were aimed at identifying the immunological events that follow infection and the varicella protein(s)
that might serve in potential VZV vaccines; however, these investigators became interested in VZV
pathogenesis, about which about they have learned a great deal from studies of the infection of human
tissue implanted into mice with severe combined immunodeficiency (SCID-hu mice) [25].
2.3. Recent Studies of VZV in Guinea Pigs
Gershon and colleagues [26,27] originally used guinea pigs as a source of neurons to investigate
lytic, latent and reactivating VZV infection in vitro. At that time, VZV was thought to exhibit a
tropism for sensory neurons because the virus was known to establish latency in neurons of dorsal
root (DRG) and cranial nerve (CNG) ganglia. Human DRG and CNG neurons can be obtained
from cadavers or aborted fetuses, but neither source is ideal for laboratory experiments. Intrinsic
primary afferent neurons (IPANs), thought to be analogous to the sensory neurons of DRG and CNG,
are abundant in the enteric nervous system (ENS) [28,29], and guinea pig enteric neurons are readily
isolated and cultured [30]. Thus, Anne and Michael Gershon tested the hypothesis that VZV would
preferentially infect IPANs in neurons isolated from the guinea pig ENS. VZV, however, infected all
enteric neurons in vitro, with no preference for IPANs. In humans, moreover, after an episode of
varicella or inoculation with the live attenuated VZV vaccine, VZV establishes latency, not just in
DRG and CNG, but also in ganglia of the autonomic nervous system, including those of the ENS
and sympathetic nervous system [31–35]. The Gershons also noticed an interesting dichotomy in
their cultures of guinea pig enteric neurons. When fibroblasts were present in the VZV inoculum,
as they were when cell-associated VZV was used to infect cultures or when fibroblasts were included
with enteric neurons at the time of isolation, the infection of neurons induced expression of VZV
glycoproteins, caused rapid cell death, and thus appeared to be lytic [30,36,37], whereas use of cell-free
VZV led to apparent virus latency. Neurons with apparent latency did not express VZV glycoprotein
and survived for as long as cultures could be maintained. Interestingly, VZV could be reactivated from
latency by expressing either VZV open reading frame (ORF) 61 or its orthologue in herpes simplex
virus type 1 (HSV-1), infected cell polypeptide 0 (ICP0), in the infected neurons. Reactivation was
evidenced by expression of VZV glycoproteins, death of the infected neurons within 48–72 hours,
electron microscopic detection of gE-immunoreactive virions and infection of co-cultured human
melanoma (MeWo) cells. This dichotomy suggested that the absence of ORF61 at the time of infection
resulted in latent infection of neurons. While such a role for ORF61 awaits confirmation, the work with
guinea pig neurons in vitro led to an investigation of whether VZV infects neurons of the human ENS
in situ. Studies of the human gut suggested that VZV may be latent in the ENS of many individuals
who have either experienced varicella or been vaccinated against it [33–37].
After a successful infection of isolated guinea pig neurons with VZV in vitro and the demonstration
that VZV is a natural ENS pathogen, experiments were carried out to reevaluate in vivo VZV infection
and latency in guinea pigs. A new two-step approach was used, involving confirmation that VZV
established latency in the DRG, CNG and the ENS of guinea pigs after viremia induced by infusion
of VZV-infected lymphocytes, followed by the administration of tacrolimus to reactivate the virus,
a step based on the successful use of tacrolimus-induced immunosuppression to reactivate simian
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varicella virus in monkeys [38]. VZV was shown to infect guinea pig lymphocytes as well as
human lymphocytes [39]. The infection of peripheral blood mononuclear cells was primarily of
CD3-immunoreactive T cells. When given intravenously to guinea pigs, VZV-infected lymphocytes
led to latent infection in virtually every neuron of the ENS as well as the DRG [39]. No visible illness
resulted. VZV-infected animals survived at least six months, maintaining normal activity and gaining
weight. Later, however, tacrolimus in combination with corticotrophin-releasing hormone (a molecular
mimic of the effects of stress) caused VZV reactivation and a condition resembling a disseminated
zoster [40]. Use of a GFP-expressing virus driven by the VZV ORF66 promoter (provided by Dr.
Paul Kinchington) revealed patches of green fluorescence in the skin of the hairless guinea pigs upon
illumination with a Wood’s lamp (Figure 1). The animals with reactivating VZV lost weight rapidly
and were euthanized when weight loss exceeded 20–25% of the initial body weight. VZV DNA and
transcripts were detected in the blood, colon, ileum, DRG, liver, pancreas, heart, skin and kidney.
Interestingly, studies have shown that an injection of VZV into the skin of an immunocompetent guinea
pig or the direct injection of cell-free VZV into the guinea pig’s ENS can also induce latent infection
of enteric neurons. Small numbers of DRG neurons were found with retrograde tracers to project
to both the skin and the gut [40]. Interestingly, ORF63 protein is detectable immunocytochemically
in enteric neurons with latent VZV infection [40]. Although transcripts encoding ORF63 have been
observed in latently infected human neurons, the expression of ORF63 protein is controversial. It is
thus conceivable that VZV latency in guinea pig enteric neurons is not identical to that in human DRG
or CNG with respect to expression of ORF63 protein. Recently, Depledge and colleagues [41] identified
a spliced VZV mRNA antisense to VZV open reading frame 61 (VLT), a spliced transcript encoding a
protein with late expression kinetics in lytically infected cells in vitro and in zoster lesions, which is
expressed during latency in human neurons. VLT suppresses ORF 61 gene expression in co-transfected
cells, suggesting a mechanism by which it may contribute to maintenance of viral latency. Analysis of
ganglia from guinea pigs latently infected with VZV for VLT will provide additional insight into the
guinea pig model.
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(VZV). A hairless guinea pig was inoculated with lymphocytes infected with VZV modified to express
GFP under the control of the promoter for open reading frame (ORF) 66. ne month later, the animal
was treated with tacrolimus to induce immunosuppression and with corticotrophin-releasing hormone
to mimic stress. Patches of green fluorescence appeared on th skin, simultaneously with severe
weight loss.
2.4. Concluding Remarks on the Guinea Pig Model
Viremia inevitably occurs during varicella [42]. T-cells carry VZV through the circulation, enabling
VZV to reach not only DRG and CNG, but also the ENS [33,34] and other autonomic neurons [31].
If VZV reactivates in neurons that project to the skin, the diagnosis of zoster is relatively straightforward.
When VZV reactivates in neurons that lack cutaneous projections, the diagnosis of zoster is rarely
even suspected. Visceral pain and obvious intestinal involvement may occur during varicella and,
when it oes, the manifestation is th ught to be omin us [43–49]. The ability of VZV-infected
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CD3-immunoreactive guinea pig lymphocytes to transmit infection to guinea pig enteric neurons,
which remains latent, may thus truly mimic human VZV disease. It is not clear why the infection
transmitted by lymphocytes to enteric and DRG neurons is preferentially latent; the phenomenon may
have evolved to foster the survival of the host and thus persistence of the virus. Enteric neurons may
not be the primary target of VZV traveling from their site of proliferation in the tonsils to the skin,
from which they can be disseminated to infect new hosts. However, destruction of the ENS would
not serve VZV. An intact ENS is essential for life, and latency allows both the virus and the host to
continue living. Once the ENS has been infected, however, VZV can and does reactivate there [35].
Minor localized enteric reactivations might even be useful in maintaining long-term immunity to
VZV. The gut contains so many immuno-effector cells that low-level viral reactivation would likely
be controlled before they produce extensive damage. However, if reactivation within the ENS is not
controlled, enteric zoster, which can lead to lethal pseudo-obstruction or perforation of the bowel,
can occur [35,40]. The guinea pig VZV model in which both latency and reactivation can be studied may
provide novel insights into the still unknown mechanisms by which infected lymphocytes transmit
viral latency to ENS neurons, the provocateurs of VZV reactivation within enteric neurons, the signs
of enteric zoster and the potential contributions of enteric zoster to the burden of gastrointestinal
illness. Finally, subject to availability of guinea pig-specific reagents, innate and VZV-specific adaptive
immunity can be studied during VZV infection and reactivation.
3. Cotton Rat Model
The cotton rat has been used in models of numerous virus infections, including respiratory
syncytial virus, influenza virus, parainfluenza virus, measles virus, hantavirus, adenovirus and herpes
simplex virus. Infection of cotton rat fibroblasts with VZV results in productive infection (unpublished
observations). Inoculation of cotton rats intramuscularly along the side of the thoracic and lumbar
spine with cell-associated virus results in a latent virus infection, with VZV DNA in the DRG. A viral
transcript that is expressed during latency in human ganglia, ORF63, is also expressed in cotton rat
ganglia, while another transcript which has rarely been detected during latency in humans, ORF40,
is usually not expressed in ganglia of latently infected cotton rats [50]. It is important to note that
neither acute infection (varicella) nor virus reactivation (zoster) has been shown to occur in cotton rats
after inoculation with VZV. Thus, while VZV DNA and RNA are detected in the ganglia of cotton rats
and resemble the same viral nucleic acids seen in latently infected human ganglia, the possibility of an
abortive infection in the ganglia of cotton rats cannot be excluded. Detection of VLT [41] in ganglia
from cotton rats at later times following inoculation may help determine the status of infection.
The role of many VZV genes in latent infection has been studied in the cotton rat. Several virus
genes, ORF1, ORF2, ORF10, ORF13, ORF17, ORF21, ORF 32, ORF47, ORF 57, ORF61 and ORF66, have
been shown to be dispensable for latent infection in cotton rats based on the infection of animals with
VZV with deletions or stop codons in the genes [50–54]. While VZV mutants in most of these genes
grow to wild-type levels in vitro, three exceptions are noteworthy. First ORF21, which is essential for
growth in cell culture, was dispensable for the establishment of latency [54]; however, since cotton rats
were inoculated with complementing cells expressing ORF21, the abundance of the ORF21 protein may
have helped the virus to establish latency. Second, while VZV deleted in ORF17 is severely impaired
for replication in cell culture at 37 ◦C, the mutant virus established latency at levels similar to those of
wild-type virus in cotton rats, which have a core temperature of 39 ◦C [51]. Third, while growth of
VZV deleted for ORF61 is severely impaired in the cell culture, the virus establishes latency at levels
similar to those of the wild-type virus [52].
VZV with deletions or stop codons in other genes, ORF4, ORF29 and ORF63, shows impaired
latency and lower levels of viral DNA in DRG of cotton rats compared with animals infected with
wild-type virus [55–58]. ORF4 and ORF29 are essential for growth in cell culture and can only be
grown in cells expressing the proteins. In each of these experiments, VZV was passaged once in
non-complementing cells, and animals were inoculated with non-complementing cells containing the
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virus. ORF63 is the most abundant transcript in latently infected human ganglia [59], and its deletion
results in impaired virus replication in culture. Cotton rats inoculated with VZV deleted for ORF63 had
levels of VZV DNA in their ganglia similar to those in animals inoculated with VZV expressing ORF63
at three days after infection; however, at six weeks, both the percentage of latently infected animals
and the viral load in the ganglia were reduced in the animals infected with VZV deleted for ORF63 [55].
Use of VZV with different mutations in ORF63 revealed a strong correlation between mutants impaired
for replication in cell culture and those impaired for the establishment of latency [56].
The cotton rat model was used in developing a VZV mutant that was impaired for latency, but not
for replication, in vitro [60]. VZV with deletions in portions of ORF62 and ORF63 and rearrangements
in the 3’ portion of the genome was found to replicate to wild-type titers in the cell culture, induce
high titers of neutralizing antibody in guinea pigs and was significantly impaired for latency in cotton
rats. Thus, the establishment of latency with the mutant virus did not strictly correlate with virus
replication in vitro. This VZV mutant could represent a safer vaccine, since it might be less likely to
reactivate from latency.
Overall, the cotton rat model has several features that make it an attractive model to study VZV.
Animals can be reliably infected with the virus, and a transcript expressed during latency in human
ganglia (ORF63) is also expressed in cotton rat ganglia, while a transcript rarely expressed during
latency in humans (ORF40) is also usually not expressed in latently infected cotton rats. Ganglia can be
removed immediately after death to reduce the risk of postmortem virus reactivation, and the level of
latent VZV can easily be quantified in ganglia. However, like all small animal models of VZV, infection
of cotton rats does not result in acute disease (varicella) or virus reactivation (zoster), and unlike human
ganglia, explanted ganglia from cotton rats do not undergo viral reactivation. In addition, compared
with other small animal models, cotton rats are difficult to work with since they are very aggressive
animals, immunologic reagents are much more limited for these animals than for mice, and fewer
suppliers sell these animals; accordingly, this model has not been used for different studies, including
innate adaptive immunity of VZV, by researchers other than those who originally reported its use.
4. SCID-hu Mouse Model
While the human-restricted nature of VZV has hindered the study of VZV infection in small animal
models, the use of intact human (hu) tissue xenografts in mice with severe combined immunodeficiency,
i.e., SCID-hu mice, has facilitated in vivo investigations of the molecular mechanisms of VZV
pathogenesis [61,62]. VZV replication in human DRG xenografts recapitulates many aspects of
ganglionic infection during initial infection and reactivation from latency. Replication is limited to the
xenograft because of the host restriction, enabling long-term studies in the absence of VZV-specific
adaptive immunity, which is lacking in SCID mice. Here, we highlight valuable insights into the
molecular basis of neurotropism made using the SCID-hu DRG model to reveal VZV interactions with
differentiated human neural cells examined in their DRG tissue microenvironment and to define viral
determinants of neurotropism in vivo with recombinant viruses containing targeted mutations in VZV
genes [25,63].
Briefly, DRG were dissected from fetal spinal tissue (18 gestational weeks, Figure 2, Panel IA),
procured by Advanced Bioscience Resources (Alameda, CA) in accordance with state and federal
regulations [61]. A single ganglion (~2 mm3) was surgically implanted under the left renal capsule
of a sedated six-week-old male scid/scid homozygous C.B.17 mouse (Figure 2, Panel IB). Histologic
evaluation of DRG xenografts after four weeks demonstrated the expected organotypic architecture,
in which neuronal cell bodies and their encapsulating satellite glial cells (SGCs) resided within a
network of axons and other supportive cells [61]. Endothelial cells within the DRG microvasculature
expressed the human-specific cell marker PECAM-1 [61]. Human DRG neurons expressed neural cell
adhesion molecule (NCAM) and synaptophysin. NCAM+ nerve bundles are observed extending
throughout the DRG xenograft as well as into the murine renal tubule network. At 20 weeks, nociceptive
and mechanoreceptive neurons, the major neuronal subtypes present in postnatal and adult human
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ganglia, were readily distinguished using peripherin immunoreactivity and RT97 immunoreactivity,
respectively [64]. DRG xenografts were maintained in SCID mice for an extended period of time
(>1 year). The capacity for human neurons to survive long-term and extend axons throughout the
xenograft and into the mouse renal tissue indicate that growth properties of differentiated DRG neurons
are intact despite the absence of orthotopic synaptic partners. VZV inoculation of DRG xenografts
resulted in productive infection and was accomplished by direct injection of VZV-infected fibroblast
cells into the exposed xenograft [61]. Importantly, intravenous administration of VZV-infected T-cells
also resulted in DRG infection, supporting the concept that VZV gains access to sensory ganglia
during the cell-associated viremia characteristic of varicella [60]. VZV-infected DRG were recovered
7–28 days after inoculation to assess acute replication and at >56 days to assess the latent phase,
as described [61,62,64–68].
The acute replicative phase of DRG infection (7–28 days after inoculation) is characterized
by extensive cytopathic changes, the fusion of neurons with their surrounding satellite cells to
form polykaryons and the production of infectious virus in both neurons and satellite glial cells
(SGCs) [61,66]. The histologic appearance of VZV DRG during the acute phase (Figure 2, Panel
IC) is similar to descriptions of cadaver ganglia recovered from patients with zoster at the time
of death [68]. As observed in ganglion neurons of zoster patients, VZV infection elicits dramatic
changes in the DRG xenograft cytokine milieu, including increased production of cytokines associated
with neuroinflammatory responses (MCP-1/CCL2, IL-1α, RANTES and IP10/CXCL10) [64]. Profiling
VZV susceptibility of neuronal subtypes revealed that RT97+ mechanoreceptive neurons are more
resistant to VZV replication compared with peripherin+ nociceptive neurons (Figure 2, Panel II) [64].
This restriction occurs after entry and ORF61 expression, but prior to IE63 protein expression, indicating
that VZV replication is repressed very shortly after mechanoreceptive neurons are infected.
VZV and HSV-1 infection of DRG xenografts differ significantly, in that HSV-1 infects neurons
only; the capacity of VZV to infect SGCs and fuse neurons and SGCs is unique [69]. Of note, neuronal
subtypes that restrict HSV-1 and HSV-2 infection have been defined in a mouse ganglia model [70],
suggesting that human alphaherpesviruses may have evolved tropism for skin-resident nociceptive
nerve endings as a portal to neuronal ganglia. The state of VZV in DRG xenografts after the replicative
phase resembles VZV latency as described in human cadaver ganglia obtained from seropositive
patients without evidence of zoster at the time of death, i.e., viral genomes persist in the absence of
infectious virus production. Viral transcription during this phase is highly restricted; ORF63 transcripts
are present at low levels. This transition is unique to neurons within the DRG microenvironment,
contrasting dramatically with the progressive lytic infection observed in skin and T-cell xenografts,
and occurs despite the absence of adaptive immune responses [25]. The extent to which VZV genes
are transcribed and translated during latency has been challenging to resolve using cadaver ganglia
because activation of the entire VZV transcriptome, in particular ORF63 transcript levels, was shown
to increase in proportion to the postmortem interval [71]. In addition, endogenous antibodies directed
against blood group A1-associated antigens present in animal sera and ascites-derived antibody
preparations used to detect IE63 protein produce a staining artifact in cadaver ganglia that can be
misinterpreted as VZV-specific staining due to neuronal A1 expression [72]. Experiments using DRG
xenografts to investigate VZV neurotropism as well as to examine cadaver ganglia after adsorption of
sera or ascites against blood group A1 erythrocytes have demonstrated that VZV protein expression
is not a characteristic of latency (Figure 2, Panel I) [72,73]. Investigation of VZV reactivation in the
SCID-hu DRG model has been challenging due to the absence of a marker to identify latently infected
neurons. The presence of VLT [41] has not been assayed in the SCID-hu model. DRG xenograft
experiments also revealed that subnuclear domains known as promyelocytic leukemia protein nuclear
bodies (PML-NBs), or ND10 bodies, serve as an intrinsic defense (Figure 2, Panel III). Large PML-NBs,
consisting of PML fibers that sequestered newly assembled nucleocapsids (NC) in spherical cages,
were identified in neurons and satellite cells [74]. Preventing nuclear egress of NCs was identified as a
basic cytoprotective function of PML in DRG as well as skin.
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Figure 2. Varicella-zoster virus (VZV) infection of SCID-hu dorsal root ganglia (DRG) xenografts.
Panel I. (A) Tissue section of fetal gestational DRG (18 gestational weeks) prior to implantation,
stained with hematoxylin and eosin. (B) Appearance of DRG xenograft at four weeks post-transplant
(arrow). (C) VZV-antigen immunohistochemistry in a tissue section of VZV-infected DRG during
acute infection (brown signal indicates VZV protein in neurons (thick arrow) and satellite cells (thin
arrow)). (D) Tissue section from a human cadaver DRG after VZV-antigen immunostaining, where
numbers denote two different staining artifacts that occur when staining cadaver DRG tissue sections:
1, lipofuscin reactivity, which appears green upon counterstaining with azure blue; and 2, reactivity
of blood group A1-associated antigens. Panel II. Primary VZV infection in respiratory epithelial cells
(A) enables T-cell-mediated spread (B) to skin (C), followed by retrograde axonal transport to DRG
neurons (D) or direct T-cell-mediated spread to DRG (E), which facilitates satellite glial cell (SGC)
infection. VZV infects both nociceptive (small, orange) and mechanoreceptive (large, green) neuron
cell bodies, but replication is severely restricted in mechanoreceptive neurons. If neuronal replication
is uncontrolled, SGC infection facilitates spread to neighboring non-neuronal satellite cells (F) and
associated neuronal cell bodies, amplifying VZV retrograde transport to skin. SGC infection also
contributes to neuronal cell loss, resulting in satellite cell microproliferations (nodules of Nageotte; G).
Panel III. Upper: Neural cells have large ring-like promyelocytic leukemia (PML) cages (green, white
arrows), where ORF23 capsid protein localizes (red). Lower: PML-specific immunogold-labeling of
ultrathin cryosections shows that PML cages (PML, 15 nm; arrowheads) sequester VZV nucleocapsids
(arrows) in infected neural cells. Areas in black squares (i and ii) are shown at higher magnification in
right panels.
Viruses 2019, 11, 502 9 of 25
Analyses of VZV determinants of neurovirulence have focused on strain comparison (vaccine and
clinical isolates) and the use of VZV recombinant viruses generated by overlapping cosmid or bacterial
artificial chromosome (BAC) systems. Importantly, infection of DRG xenografts using live attenuated
varicella vaccine virus demonstrated that vaccine Oka (vOka) exhibits the same pattern of acute
replication followed by viral DNA persistence as two clinical isolates, parent Oka virus and VZV-S [61].
The experiments suggest that vOka attenuation by serial passage in cultured cells does not alter
infectivity for neurons or the capacity to establish a transcriptionally repressed latent state, consistent
with the clinical evidence that vOka can establish latency and reactivate to cause zoster. Experiments
to identify VZV determinants of neurovirulence using VZV recombinant viruses have focused on VZV
ORF68-encoded glycoprotein gE and ORF67-encoded gI, which are type I membrane proteins that
participate in cell–cell spread and secondary envelopment [75]. Those experiments demonstrated that
gE interaction with the insulin-degrading enzyme, identified as a possible cellular entry receptor, is not
required for neurotropism, whereas the gE interaction with gI to form heterodimers as well as specific
gI functions needed for virion assembly and egress are critical for VZV replication in DRG in vivo [65].
Notably, disrupting gE–gI binding resulted in chronic low-level replication and extensive destruction
of DRG cells, indicating that preservation of the gE–gI interaction is necessary for the transition to
VZV persistence in neurons.
In summary, the SCID-hu DRG model has enabled substantial progress in the understanding VZV
virulence factors and neurotropism. That VZV exhibits tropism for both neurons and SGCs and can
cause fusion of these unique cell types distinguishes VZV from HSV neuropathogenesis, and helps
to explain the often prolonged recovery from zoster and the occurrence of post-herpetic neuralgia.
While this review is restricted to neurotropism, it should be noted that SCID-hu model is useful for
studies of innate immune response. Although many questions remain, further advances are expected
to provide better insight into the clinical manifestations of varicella and herpes zoster.
Application of the SCID-hu Mouse Model to Study VZV ORF7 Neurotropism
VZV encodes 70 unique ORFs. In a genome-wide mutagenesis study, each of the VZV ORFs
was individually deleted using VZV BAC technology [76]. That study showed that 52 of 70 ORFs are
essential or critical and 18 of them are dispensable for viral replication in MeWo (human melanoma)
cells [77]. To identify the factors required for VZV neuronal invasion, latency and pathogenesis,
the 18 non-essential ORF mutants were first used to infect human differentiated neuroblastoma and
embryonic stem cell-derived neurons. Of the mutants screened, only the ORF7 mutant (7D) failed to
grow and spread in the neurons [78], suggesting that ORF7 encodes a neural tropic factor.
To further test ORF7 neurotropism in more physiologically relevant systems, the SCID-hu DRG
xenograft mouse model was used [61]. A human fetal DRG xenograft (Figure 2A,B) was implanted
under the kidney capsule of a SCID mouse. Four weeks post-xenotransplantation, the DRG was
surgically exposed and directly injected with 100 PFU of the wild-type (WT), ORF7 deletion mutant
(7D) and 7D rescue (7R) VZV (Figure 3D). Since the viruses contained the luciferase marker, the viral
replication in vivo was measured for 10 days using the In Vivo Imaging System; no luminescent
signal was detected in the 7D-infected SCID-hu DRG xenograft (Figure 3C,D). Importantly, 7R grew
at the same rate as did the WT, demonstrating that the defective phenotype of 7D is fully restored
by rescuing ORF7. Histochemical analysis and immunostaining of the harvested and fixed infected
DRG grafts (Figure 3E) revealed abundant VZV gE antigen in WT- but not in 7D-infected neurons
or surrounding satellite cells. For WT, the pervasive presence of gE antigen indicates active viral
replication. Vacuolar structures might indicate the formation of neuron-satellite cell complexes or
satellite cell polykaryon (arrows in Figure 3E). In contrast, 7D was unable to propagate within the
implant, as suggested by the absence of gE antigen, such that the appearance of the DRG is that of a
normal tissue. As shown in Figure 3F, fluorescence in situ hybridization of DRG xenografts using a
whole-VZV genome fluorescently labeled probe revealed the widespread presence of viral DNA in the
nuclei of WT-infected neurons (red arrowheads) and satellite cells (white arrowheads). Clustering of
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viral DNA in specific intranuclear replication centers is an indication of productive replication (bright
green fluorescence). In contrast, no viral DNA was detected in the 7D-infected sample (Figure 3E),
consistent with the results of the immunohistochemistry analysis. These results indicate that the
absence of ORF7 from the viral genome prevents the VZV spread in human DRG tissue.
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Figure 3. ORF7 is essential for viral replication in human neurons in vivo. (A) Human dorsal root 
ganglia (DRG) isolated from the fetal spinal cord. (B) Human DRG were implanted under the kidney 
capsule of SCID mice and four weeks later, infected with 100 PFU of cell-free wild-type (WT), the 
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Images at 10 days post-infection (dpi) are shown. (D) The total photon counts from each sample (five 
animals/viral sample) were quantified, analyzed and used for generating growth curves. (E) At 10 
dpi, WT- and 7D-infected DRG harvested from SCID mice were stained for gE (brown) and 
counterstained with hematoxylin (blue). Lower panels represent a higher magnification of selected 
areas of the upper panels. Red arrowheads indicate neurons. Vacuolization and possible 
neuron-satellite cell aggregates (black arrows) were observed in the WT-infected sample, correlating 
with productive replication and widespread presence of viral gE antigen (brown), while 7D samples 
retained normal DRG morphology and no gE was detected. (F) Fluorescence in situ histochemical 
staining of the infected DRG samples using a VZV genomic DNA probe (green) revealed 
intranuclear signals from nuclei of both neurons (red arrowheads) and adjacent satellite cells (white 
arrowheads) in WT-infected tissue, indicative of active viral DNA replication within intranuclear 
replication centers; no 7D DNA was detected in any of the samples tested at the experimental 
endpoint. 
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Figure 3. ORF7 is essential for viral replication in human neurons in vivo. (A) Human dorsal root
ganglia (D G) isolated from the fetal spinal cord. (B) Huma DRG were implanted unde the
kidney capsule f SCID mice and four weeks later, infected with 100 PFU of cell-free wild-type (WT),
the ORF7-deleted mutant (7D) or the 7D rescue (7R) VZV, respectively. (C) The bioluminescence
signal recor ed in SCID mice every other day after int aperiton al administration of D-luciferin for
10 days. Images at 10 days post-infection (dpi) are shown. (D) The total photon cou ts from each
sample (five animals/viral sample) were quantified, analyzed and used for generating growth cur s.
(E) At 10 dpi, WT- and 7D-infected DRG harvested from SCID mic were stained for gE (brown) and
counterstai ed with hematoxylin (blue). Lower panels represent a higher magnification of selected areas
of the upper panels. Red arrowheads indicate neurons. Vacuolization and possible neuron-satellite
cell aggregates (black arrows) were observed in the WT-infected sample, correlating with productive
replication and widespread presence of viral gE antigen (brown), while 7D samples retained normal
DRG morphology and no gE was detected. (F) Fluorescence in situ histochemical staining of the
infected DRG samples using a VZV genomic DNA probe (green) revealed intranuclear signals from
nuclei of both neurons (red arrowheads) and adjacent satellite cells (white arrowheads) in WT-infected
tissue, indicative of active viral DNA replication within intranuclear replication centers; no 7D DNA
was detected in any of the samples tested at the experimental endpoint.
5. Simian Varicella Virus (SVV) Infection in Non-Human Primates (NHP)
5.1. Molecular Aspects of SVV
Simian herpesviruses were identified as the causative agent responsible for epizootic outbreaks
of monkey chickenpox in Old World monkeys [79]. Virus isolates were initially named for the
geographical location of the epizootic and/or the monkey species (i.e., Liverpool vervet virus, Medical
Lake macaque virus and Delta herpesvirus). Subsequent molecular analyses of viral DNA derived
from these distinct outbreaks confirmed that the epizootics were caused by the same infectious agent,
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which was named simian varicella virus (SVV) [80], which is now classified as Cercopithecine herpesvirus
9 within the Varicellovirus genus of alphaherpesviruses.
In the laboratory, SVV is grown in cell cultures of simian origin, usually African green (Vero, BSC-1,
CV-1) or rhesus (LM-MK2) monkey kidney cells [81]. Infected cell monolayers exhibit a cytopathic
effect, with multi-nucleated cells. Electron microscopy reveals viral nucleocapsids within the cell
nucleus [79]. In addition, abundant degraded viral particles are detected within cytoplasmic vacuoles,
apparently caused by virion sensitivity to cellular lysosomal enzymes. Consequently, SVV-infected
monolayers generate a low titer of infectious virus (102–104 plaque-forming units per ml) compared to
many other herpesviruses. Such is also the case for VZV grown in vitro [82]. SVV and VZV mature as
cell-associated viruses, since relatively little infectious viruses are released from infected cells into the
culture medium.
SVV virions have typical herpesvirus morphology containing at least 30 protein species ranging
in size from 16 to >200 kD, including at least six envelope glycoproteins (46–115 kD) [83]. SVV and
VZV proteins share extensive antigenic cross-reactivity, as demonstrated by the cross-reactivity of
sera derived from SVV-infected animals and from herpes zoster patients with VZV and SVV antigens,
respectively [84], and by the finding that monkeys experimentally immunized with VZV are protected
from acute simian varicella infection following an SVV challenge [85].
Although SVV and VZV are two different viruses, their genomes are similar in size, structure,
genetic content [86–88] and pattern of disease produced in their respective hosts. SVV DNA consists of
124,785 base-pairs (bp), 99 bp shorter than VZV DNA, with a 40.4% G + C content comparable to that
of VZV DNA (46.0%) [89]. Similar to VZV DNA, the SVV genome is composed of a 104-kbp unique
long (UL) component bracketed by a 64-bp inverted repeat sequences and a short (S) component
composed of a 4.9-kbp unique short (US) region bracketed by 7.6-kbp inverted repeat sequences. SVV
DNA encodes 69 distinct SVV ORFs, each sharing 27–75% amino acid identity to corresponding VZV
genes [90]. Like VZV DNA, the SVV genome includes three ORFs (62–64) that are duplicated within
the S segment. However, a VZV ORF 2 homologue is missing in the SVV genome. SVV and VZV
genomes differ only in the 3-kbp sequence at the left end of the genomes (Figure 4) [91]. The function
of SVV ORF B (VZV ORF 0 or S/L) is unknown. Based on their homology to VZV ORFs, SVV ORFs 1
and 3 probably code for membrane and virion assembly proteins, respectively. SVV does not contain
ORF 2. SVV ORF A, not present in VZV is homologous to the C-terminal end of SVV ORF 4, which
codes for an immediate early gene and is a transactivator.
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coordinately regulated into immediate early (IE), early and late phases. SVV ORF62 encodes a major 
transactivator protein (IE62), which is expressed early in infection and induces transcription of SVV 
IE and early genes [92]. SVV IE ORF61 and 63 also encode transcriptional activators [93]. SVV early 
genes, which are involved in viral DNA replication, include deoxyUTPase (ORF8), ribonucleotide 
reductase (ORF19), thymidine kinase (ORF36) and uracil DNA glycosylase (ORF59) [94,95]. The viral 
Figure 4. Sequence organization at the left ends of VZV and simian varicella virus (SVV) genomes.
TRL—terminal repeat sequences; UL—leftmost part of the unique long segments. SVV ORF B is
homologous to VZV ORF S/L. ORFs A and Q (blue) are present in SVV but not VZV, whereas ORF2
(green) is present in VZV but not SVV.
Like other herpesviruses, SVV gene expression during viral replication is understood to be
coordinately regulated into immediate early (IE), early and late phases. SVV ORF62 encodes a major
transactivator protein (IE62), which is expressed early in infection and induces transcription of SVV IE
and early genes [92]. SVV IE ORF61 and 63 also encode transcriptional activators [93]. SVV early genes,
which are involved in viral DNA replication, include deoxyUTPase (ORF8), ribonucleotide reductase
(ORF19), thymidine kinase (ORF36) and uracil DNA glycosylase (ORF59) [94,95]. The viral capsid
proteins and several envelope glycoproteins, including SVV gB (ORF31), gC (ORF14), gE (ORF68), gH
(ORF37) and gL (ORF60), are expressed during the late phase of viral replication [89,96–98].
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During acute varicella infection of NHP, most of the SVV genome is transcribedd, as confirmed by
the transcriptome analysis of bronchial alveolar lavage (BAL) cells and peripheral blood mononuclear
cells (PBMCs) [99]. SVV IE ORF63 and ORFs41 and 49, which encode structural proteins, are abundantly
expressed during an acute disease. In contrast, SVV gene expression is restricted during viral latency.
An SVV latency-associated transcript (LAT), identical to VLT [41], is predominately expressed in cells
of neural ganglia derived from latently infected nonhuman primates [99,100]. Similar to VLT, SVV LAT
is transcribed anti-sense to the SVV ORF61 transactivator gene. Although SVV LAT was discovered
first, it is not as well characterized as VLT. The simian varicella model provides a useful approach to
further explore the role of VLT in viral latency.
SVV infection of non-human primates (NHP) provides the only experimental animal model that
closely simulates human varicella and studies involving innate and adaptive immunity. The study
of SVV molecular biology and pathogenesis is facilitated by the ability to generate gene-specific
viral mutants. Initially, an SVV cosmid recombination system for generating SVV mutants was
used [101], in which SVV DNA fragments (30–45 kb) collectively composing the entire SVV genome
were cloned into four overlapping SVV cosmids. Transfection of these cosmids into Vero cells and
homologous recombination generated infectious SVV. Site-specific mutations introduced into individual
cosmids have facilitated the generation of SVV gene mutants, including SVV gC–, ORF61–, UDG–
and dUTPase [93,101,102]. Similarly, the cosmid system has been used to construct recombinant
SVVs expressing foreign genes such as those encoding simian immunodeficiency virus (SIV) gag and
env antigens [103]. More recently, the entire SVV genome has been cloned into a BAC, permitting
propagation of the SVV DNA in Escherichia coli and facilitating the generation of SVV mutants and
recombinant viruses [104–106]. SVV derived from this SVV-BAC is pathogenic upon infection of
infected rhesus monkeys and establishes latent infection in neural ganglia [107].
5.2. Primary SVV Infection and Latency
Despite being a different herpesvirus infecting a different host, SVV is pathogenic in NHP causing
an acute respiratory infection with varicella (chickenpox) and later establishment of latency in sensory
and enteric neurons, similar to disease produced by VZV infection in humans. Multiple species of
NHP are susceptible to natural SVV infection [79,108,109]. Further development of NHP as animal
models using experimental intratracheal, intrabronchial or natural aerosol routes for SVV inoculations
demonstrated distinct species-specific patterns of disease [110–114]. Experimental infection of African
green monkeys (AGM) leads to severe, sometimes fatal hemorrhagic disease (Figure 5A), whereas
Indian rhesus macaques (RM) and cynomolgus macaques develop a less severe disease that is more
similar to humans [110–113,115]. SVV inoculation in Chinese RM was shown to develop immune
responses without a skin rash [116]. Subspecies differences in disease course between Chinese and
Indian RM have also been observed in SIV infections [117]. Similarly, unlike macaques, non-macaques
infected with herpes B virus can suffer fatal encephalitis [118].
Experimental respiratory inoculations of SVV in AGM results in an infection of epithelial, myeloid
and lymphoid cells. A Virus then enters the bloodstream infecting PBMCs to cause a viremia, with
further hematogenous dissemination to the skin, lymph nodes, spleen and other organs [114,119].
Peak SVV-infected cell numbers are seen in BAL at 3–9 days post-infection (dpi), while SVV viremia
is observed as early as 3–4 dpi in AGM and RM [112,120,121], with infection of all major PBMCs
including T- and B-lymphocytes, natural killer cells, monocytes and dendritic cells in AGM [114].
In RM, in some instances, very low viremia was seen at 7 dpi with robust SVV replication in lungs
and the virus did not infect B cells [122]. Strong pulmonary innate immune cytokine and chemokine
responses during acute infection are also seen in RM correlating with low viremia [123,124]. RNA
sequencing studies on tissues from SVV-infected RM have demonstrated that virus spreads rapidly
through the lungs, replicating both in the immune cells and parenchyma [125]. Acute infection is
characterized by significant immune infiltration and reduced expression of genes important for lung
function, indicative of lung injury and viral pneumonia. This is followed by increased expression
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of genes important for host defense, which correlates with viral clearance. Finally, the expression of
growth factors and cell cycle-associated genes increases to usher in the repair phase [125].
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Figure 5. Varicella and zoster rash in non-human primates (NHP). (A) A hemorrhagic varicella rash in
an African green monkeys (AGM), 13 days post-intratracheal inoculation and (B) a zoster rash in a
late tly infected rhesus macaques (RM), seven weeks after immunos ppression. Arrows indicate the
location of rash on the skin.
The first signs of clinical disease, seen frequently in AGMs and sometimes in macaques, are a
fever and nlarged lymph nodes at 6–14 dpi [114]; Traina-Dorge, unpublished observation]. At this
time and coincident with peak viremia, animals develop a limited to widespread generalized macular,
papular and vesicular rash, with an occasional severe hemorrhagic rash in AGMs [112,113,126,127].
Viral lesions in the rash are widespread over the body, including the torso, abdomen, appendages,
face and neck. Mild hepatitis may also be present at 9–10 dpi in AGMs and RMs, with elevated liver
transaminase levels in the blood [38,112].
At 7–14 dpi, a robust adaptive immune response develops, characterized by the presence of both
binding and neutralizing antibodies and the detection of antigen-specific CD4 and CD8 central and
effector memory T-cells in both BAL and PBMC samples [79,113,114,123,128,129]. Studies using the RM
model clearly indicate a critical role for CD4 T-cell immunity in resolution of acute SVV infection [130]
and the establishment of latency [131], as well as reactivation [132,133]. As early as 3 dpi, SVV probably
traffics to the ganglia by hematogenous transport. Ganglionic infection is indicated by the detection
of SVV DNA and antigens in neurons, although virus-induced cytopathology is absent [79,134–136].
Infiltration of T-cells [122] and SVV-infected T-cells containing SVV antigen [114] surrounding the
sensory neurons have been observed, supporting their role in viral transport to ganglia. SVV infection
of ganglia is accompanied by robust changes in gene expression [122]. Differentially expressed genes
detected at 3 dpi include components of the troponin complex, which play a critical role in axonal
transport, as well as several interferon stimulated genes indicative of an innate antiviral response.
Upregulation of genes important for T- and NK cell recruitment is seen at 7 dpi, followed by significant
downregulation of genes important for neuronal function and nervous system development, which
lasts up to 100 dpi, long after cessation of viral replication. After acute infection, virus-infected T-cells
expressing the gut-homing receptor α4β7 integrin were detected in mesenteric lymph nodes that drain
into the gut, supporting the role of T-cells in viral transport to enteric neurons. SVV RNA has also been
shown in enteric neurons of latently infected monkeys, similar to observations in humans with VZV
infection [33,137].
In RM, a virus is cleared from the peripheral organs within 7 dpi, with establishment of
latency [122,138]. In the AGM model, after intratracheal inoculation, SVV DNA and RNA persist in
lung and liver for up to 10 months, in ganglia for up to 12 months and in circulating T-cells for years after
infection [111,139]. During SVV latency, the viral gene expression program is highly restricted, with only
12 ORFs detected in the ganglia of latently infected RM [99]. Among these transcripts, an ORF61
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antisense transcript was 5–9 times more abundant than a sense transcript [100,113]. As recently shown
for VZV [41], this antisense transcript is thought to abrogate ORF61 expression in order to promote the
maintenance of SVV latency. Interestingly, deletion of ORF61 from the SVV genome did not impair
establishment of SVV latency, suggesting that the absence of both ORF61 and its antisense transcript
masks their relative functions in viral latency [139].
Accumulating evidence points to the important role of T-cells in SVV dissemination, establishment
and maintenance of latency. First, it was shown that T-cells in the BAL are susceptible to and can
support SVV viral replication in vivo [140]. Moreover, memory CD4 and CD8 T-cells infiltrate ganglia
as early as 3 dpi, which correlates with the detection of viral loads and before the development of
cell-mediated immunity [122]. A recent study reported that SVV infection causes large changes in
the expression of genes that play a role in cell cycle, cellular metabolism and immune processes
in T-cells isolated ex vivo from BAL samples collected from RM at different dpi [140]. Together,
these data indicate that T-cells are susceptible and permissive SVV targets, with a critical role in viral
dissemination to the ganglia.
5.3. SVV Reactivation in NHP
A significant complication of aging is the reactivation of latent VZV, manifesting as zoster,
post-herpetic neuralgia (PHN), pneumonitis, blindness, stroke, myocardial infarction and other
multi-organ diseases. VZV latency is controlled largely by cell-mediated immunity and reactivation is
due to its decline, disruption or loss [141]. In humans, immunosuppression due to radiation therapy or
treatment with immunosuppressive drugs and/or steroids induces reactivation of VZV, causing severe
and sometimes fatal zoster, neuritis, PHN and other complications [142–144]. VZV does not reactivate
in any small animals used to study establishment of latent infection. However, SVV reactivates in
immunosuppressed pigtail, cynomolgus and RM and AGMs [108,115,145–147].
The NHP model of varicella reactivation has been successfully developed in SVV-infected
cynomolgus and RM and AGMs [120,127,142] using immunosuppression to disrupt cellular
immunity through a combination of X-irradiation, tacrolimus and prednisone (Trio XTP) to induce
reactivation of latent SVV in macaques (Figure 5B). In cynomolgus macaques, zoster developed after
immunosuppression, with SVV-antigen detected in a skin rash, sensory ganglia and the lungs. SVV
glycoproteins were also found in non-ganglionic tissues in the absence of a rash in some of the treated
monkeys and in one untreated monkey subjected to the same stress of transportation [148], indicating
subclinical reactivation.
In another study, more monkeys developed zoster when treated with tacrolimus alone rather
than with both tacrolimus and irradiation [127]. As mentioned above, tacrolimus to induce varicella
reactivation was also used in the guinea pig model [40]. Infiltration of T-cell clusters around ganglionic
neurons was seen in cynomolgus macaques that developed zoster after tacrolimus treatment. CD8
T-cells were more prevalent than CD4 T-cells around neurons. In addition, CXCL10 RNA but not SVV
ORF61 RNA co-localized with the T-cell clusters. CXCL10 RNA-positive cells were more abundant
within two months after zoster compared to the later times [149]. The T-cell clustering may be mediated
by CXCL10 and parallels the observation in autopsied ganglia of humans after zoster [150].
SVV reactivation was observed in infected RM treated with Trio-XTP [120]. Zoster rash was also
observed in an untreated monkey subjected to the same stress as treated monkeys. SVV antigens were
detected in skin, lung, lymph nodes and sensory ganglia. Viral antigens in the skin were localized in
the epidermis, around hair follicles and sweat glands; in the lung, primarily in the alveolar wall; in the
lymph nodes, colocalized mostly with macrophages, dendritic cells and, to a lesser extent, T-cells;
and in the sensory ganglia, in neuronal and non-neuronal cells. Unlike virus antigens, only minimal
levels of SVV DNA were detected in the tissues.
Similar to observations in cynomolgus macaques, numbers of circulating PBMC were significantly
reduced in RM within a week after the start of the Trio-XTP treatment [128]. Flow cytometric analyses
of blood samples after treatment revealed reduced numbers of T-cells, including naïve, memory
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and effector CD4 and CD8 T-cells. These values remained low for days to weeks after initiation of
treatment. However, five weeks before the appearance of zoster, the percent of naïve CD8 T-cells
spiked, while the abundance of memory and effector CD8 T-cells remained low in the treated, but not
in the untreated, monkeys. CD8 T-cells in the untreated monkey were also reduced after transportation
to the radiation facility, but not to the same extent as the treated animal. SVV reactivation may have
been initiated by the lack of viral control by memory and effector cells. Two weeks before zoster,
all T-cell subsets were increased, possibly as a response to virus reactivation as confirmed by the
detection of virus antigen in tissues at necropsy [120]. Programmed death receptor (PD-1), a marker of
T-cell activation, was also increased in all CD4 and CD8 T-cells during zoster compared to latency,
suggesting an antigen-driven response. PD-1 is also a marker of T-cell exhaustion that has been found
on T-cells of patients with chronic viral infections and may signal T-cell decline and exhaustion at the
time of zoster [151]. SVV-specific responses could not be confirmed due to the lack of availability of
virus-specific reagents for flow cytometry. Intracellular cytokine responses might have confirmed an
association with virus reactivation.
Assessment of cytokine and chemokine levels in serum after immunosuppression and during
SVV reactivation showed a strong increase in the pro-inflammatory mediators MCP-1, eotaxin, IL-6,
IL-8, MIF, RANTES and HGF, but lower levels of the anti-inflammatory mediator IL-1Ra in the
circulation [124]. The influx of these strong inflammatory cytokines and chemokines is consistent with
an acute inflammatory response to the reactivated virus, as observed in zoster patients as early as nine
days post-zoster [152].
Subclinical reactivation of latent SVV in RM was demonstrated using thymectomy along with
either CD4 or CD8 depletion [133]. Following treatment, initially and for the first year thereafter,
no SVV DNA was detected in the whole blood nor was any rash seen in the animals. However, within
1–2 months after a stressful event (moving the monkeys to a different room), SVV DNA was detected
in whole blood in some of the CD4-depleted and CD8-depleted monkeys, in the absence of a zoster
rash [133]. More recently, clinical reactivation of latent SVV was shown in RM after CD4-depletion,
in which circulating CD4 T-cells were reduced by more than half within a week and remained low for
two months; a zoster rash was seen in one animal with the most extensive CD4-depletion at seven
days post-treatment and in the other treated RM at 10–40 days post-treatment, with recurrent zoster
observed in one animal [132]. Although the untreated control retained normal CD4 levels, it also
developed zoster. This animal had very low SVV-specific antibody levels suggesting overall low
virus-specific immunity. SVV reactivation was confirmed by the presence of SVV antigens in multiple
tissues and virus DNA in lung and lymph nodes. Although the reason for the contrasting results in
the two studies [132,133] is unclear, both studies suggest an important role for CD4 T-cell immunity
in controlling varicella virus latency. Together, despite being an expensive model, SVV infection
in NHP continues to be an extremely valuable animal model, expanding our understanding of the
mechanisms of neurotropism and pathogenesis of varicella virus. Recently, we have shown that SVV
DNA in saliva can be used to monitor acute infection in RM [153]. Future studies using the NHP
model will include PHN, shedding of virus in saliva during reactivation, giant cell arteritis and corneal
reactivation disease.
6. Conclusions
After primary infection, VZV establishes a life-long latent infection in neurons of the cranial nerve,
dorsal root and autonomic ganglia, and reactivates later to produce several neurological disorders.
It has been a challenge to study VZV neurotropism using an animal model since the virus causes
diseases only in humans. In this review, we have described most of the animal models that have
been adopted to study VZV neurotropism. The advantages and the disadvantages of each of the
models are listed in Table 1. Attempts to infect small animals with VZV include cotton rats, guinea
pigs and SCID-hu mice. Some of the important criteria to be met by any animal model are: virus
replication in host cells, induction of varicella; ganglionic infection followed by the establishment of
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latency and the ability to reactivate to produce zoster. During VZV latency, virus nucleic acids are
seen only in ganglia, virus transcription is restricted and virus is present only in neurons and has the
ability to reactivate. Recent developments using guinea pigs for experimental VZV infection have
shown that in the absence of primary disease, virus enters the enteric ganglia and becomes latent,
suggesting the usefulness of this model to study latency and reactivation. One limit of guinea pig
studies, which might help to explain why they have not been more widely utilized, is that the infection
of animals do not mimic primary varicella. Earlier studies have shown that experimental infection of
rats and mice with VZV does not produce varicella, but at later times, the virus is found in ganglionic
neurons as well as in non-neuronal cells and in extraneural tissues. The cotton rat model has been
used not only to identify the virus genes required for ganglionic infection, but also to show restricted
transcription of VZV genes in ganglia weeks after experimental inoculation. Foot-pad inoculation
of VZV into Sprague-Dawley rats demonstrated incomplete infection but was sufficient to produce
pain behaviors that involved changes induced in neuronal populations [154]. The SCID-hu model has
been a good alternative in vivo model to study VZV neurotropism as well as the role of specific virus
genes, such as ORF7 in ganglionic infection. SVV infection of NHP has provided extremely useful
information regarding varicella pathogenesis, latency and reactivation, despite differences between
VZV and SVV with respect to: Reactivation, when VZV dermatomal rash vs. SVV whole-body rash;
the species dependency of experimental SVV infection and differences in the 3-kb sequence at the left
end of the virus genomes. Overall, the future of research on VZV neurotropism and pathogenesis rests
on the extension of the existing important animal models to determine critical virus-host immune
and neuronal cell interactions in different tissues at multiple times post-reactivation, studies that are
currently otherwise impossible in humans.
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Table 1. Evaluation of animal models of VZV neurotropism.
Animal Model Advantages Disadvantages
Guinea pig
VZV infects guinea pig cells and can proliferate.
VZV infects guinea pig enteric neurons in vitro and can establish latency if the inoculum
contains a low multiplicity-of-infection in the absence of non-neuronal cells.
VZV can be reactivated from latency in guinea pig enteric neurons in vitro by expressing ORF61.
Intravenous inoculation of VZV-infected guinea pig or human lymphocytes infects guinea pigs
and establishes latency in most, if not all, enteric and dorsal root ganglion neurons; animals
remain symptom-free for months.
A combination of immunosuppression with tacrolimus and a simulation of stress with
intravenous corticotrophin-releasing hormone can reactivate VZV from latency.
Guinea pigs are less expensive than NHP. Ganglia can be removed immediately after euthanasia,
to avoid concerns about postmortem reactivation.
Guinea pigs do not display typical varicella.
Reactivation elicits a severe disseminated syndrome, like disseminated
zoster in humans, necessitating that the animals be euthanized.
Guinea pigs have a long gestation period and thus are difficult and
expensive to breed, complicating studies of congenital VZV and VZV in
newborn animals.
Cotton rat VZV replicates in cotton rat fibroblasts in vitro.
VZV mutants can be tested.
Host proteins may not be conserved between cotton rats and humans, such
that VZV proteins may not interact with cotton rat proteins the same way.
Animals are aggressive.
Limited species-specific immunologic reagents are available.
SCID-hu mouse
Differentiated human neurons and satellite cells, along with supportive tissues within the tissue
microenvironment of the sensory ganglion, can be maintained long-term in vivo.
Typical human neuronal subtypes are maintained, allowing analysis of VZV neurotropism at the
single-cell level and comparison with HSV-1, the other neurotropic human alpha-herpesviruses.
Viral determinants of VZV neurovirulence can be defined by evaluating VZV recombinants with
targeted mutations to disrupt domains of VZV proteins.
Opportunity to document the progression of VZV infection in sensory ganglia, demonstrating
the capacity of VZV to induce fusion of neurons and satellite cells, unlike HSV-1.
Opportunity to define innate defenses mounted against VZV infection by neural cells in vivo.
Xenografts allow study of VZV infection of human DRG.
Only available in vivo model for some human viruses.
Better at reproducing the pathophysiology of human diseases and a better model for studying
tissue tropism and antivirals.
Relatively inexpensive compared to NHP.
Allow monitoring and measuring viral replication in vivo using a bioluminescence assay.
Anterograde and retrograde transport of VZV between skin and ganglia
cannot be modeled.
Lacking human immune responses.
Complicated surgery procedure.
Large experimental variation.
Human fetal tissues may be difficult to obtain.
Absence of an adaptive immune system.
NHP (SVV) Simian counterpart virus, SVV infects NHP, causes varicella, latent infection in ganglia andzoster that are similar to human VZV infection.
Expensive and need special approval.
SVV reactivation results in a whole-body rash, while VZV reactivation in
humans produces a dermatomal rash.
SVV genome contains a unique ~3 kbp sequence at the left end, not
present in VZV and potentially encoding species-specificity.
Not the human virus, VZV.
Pattern of infection is species-specific.
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